An observational study of haemophilia A patients without inhibitors using the French national claims (SNDS) database
Objectives: To describe clinical characteristics, factor consumption, and events of interest in patients with haemophilia A without inhibitors receiving prophylaxis in France, and the clinical impact of switching to Elocta® in this population.Methods: This retrospective, observational study using th...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Hematology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/16078454.2024.2320610 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846126586484490240 |
|---|---|
| author | Marc Trossaërt Aletta Falk Laurène Gautier Nana Kragh Olivia Van Hinloopen Remi Varin |
| author_facet | Marc Trossaërt Aletta Falk Laurène Gautier Nana Kragh Olivia Van Hinloopen Remi Varin |
| author_sort | Marc Trossaërt |
| collection | DOAJ |
| description | Objectives: To describe clinical characteristics, factor consumption, and events of interest in patients with haemophilia A without inhibitors receiving prophylaxis in France, and the clinical impact of switching to Elocta® in this population.Methods: This retrospective, observational study using the Système National des Données de Santé database, analysed data from patients with haemophilia A without inhibitors using prophylactic factor VIII (FVIII) replacement therapy during 2016–2019. Clinical characteristics, treatment patterns and switches, factor consumption, and rate of events of interest were determined. In a sub-cohort of patients treated with Elocta®, clinical characteristics, factor consumption, and rate of events of interest before and after switching to Elocta® were compared.Results: For 545 patients, with mean age (standard deviation [SD]) 25.4 (17.8) years, Elocta® was the most used treatment. Bleeding events and articular non-bleeding events leading to hospitalization occurred in 15.4% and 13.9% of patients, respectively, and 9.9% of patients had surgeries or procedures related to haemophilic arthropathy. The mean (SD) FVIII product consumption was 344 (93) IU/kg/month for extended half-life treatment, and 331 (98) IU/kg/month for standard half-life products. For the sub-cohort of 146 patients, bleeding events (SD) decreased from 0.32 (2.2) to 0.09 (0.42) events/patient/year (p = 0.227) after switching to Elocta®. There was no statistically significant difference in rates of factor consumption or articular non-bleeding events before and after initiation of Elocta®.Conclusion: This study provides real-world insights that advance the understanding of treatment patterns and events of interest in patients with haemophilia A on prophylactic regimens in France. |
| format | Article |
| id | doaj-art-9a278d964606439d873d08d43e64581f |
| institution | Kabale University |
| issn | 1607-8454 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Hematology |
| spelling | doaj-art-9a278d964606439d873d08d43e64581f2024-12-12T15:08:53ZengTaylor & Francis GroupHematology1607-84542024-12-0129110.1080/16078454.2024.2320610An observational study of haemophilia A patients without inhibitors using the French national claims (SNDS) databaseMarc Trossaërt0Aletta Falk1Laurène Gautier2Nana Kragh3Olivia Van Hinloopen4Remi Varin5Hemophilia Treatment Centre, University Hospital of Nantes, Nantes, FranceGlobal Medical Affairs and Clinical Science, Sobi, Stockholm, SwedenReal World Evidence Data and Analytics, Cerner Enviza, Paris, FranceGlobal Health Economics and Outcomes Research, Sobi, Stockholm, SwedenPatient Access, Sobi, Paris, FranceDepartment of Pharmacy, Rouen University Hospital, Rouen, FranceObjectives: To describe clinical characteristics, factor consumption, and events of interest in patients with haemophilia A without inhibitors receiving prophylaxis in France, and the clinical impact of switching to Elocta® in this population.Methods: This retrospective, observational study using the Système National des Données de Santé database, analysed data from patients with haemophilia A without inhibitors using prophylactic factor VIII (FVIII) replacement therapy during 2016–2019. Clinical characteristics, treatment patterns and switches, factor consumption, and rate of events of interest were determined. In a sub-cohort of patients treated with Elocta®, clinical characteristics, factor consumption, and rate of events of interest before and after switching to Elocta® were compared.Results: For 545 patients, with mean age (standard deviation [SD]) 25.4 (17.8) years, Elocta® was the most used treatment. Bleeding events and articular non-bleeding events leading to hospitalization occurred in 15.4% and 13.9% of patients, respectively, and 9.9% of patients had surgeries or procedures related to haemophilic arthropathy. The mean (SD) FVIII product consumption was 344 (93) IU/kg/month for extended half-life treatment, and 331 (98) IU/kg/month for standard half-life products. For the sub-cohort of 146 patients, bleeding events (SD) decreased from 0.32 (2.2) to 0.09 (0.42) events/patient/year (p = 0.227) after switching to Elocta®. There was no statistically significant difference in rates of factor consumption or articular non-bleeding events before and after initiation of Elocta®.Conclusion: This study provides real-world insights that advance the understanding of treatment patterns and events of interest in patients with haemophilia A on prophylactic regimens in France.https://www.tandfonline.com/doi/10.1080/16078454.2024.2320610Haemophiliafactor replacement therapyreal-world dataobservational |
| spellingShingle | Marc Trossaërt Aletta Falk Laurène Gautier Nana Kragh Olivia Van Hinloopen Remi Varin An observational study of haemophilia A patients without inhibitors using the French national claims (SNDS) database Hematology Haemophilia factor replacement therapy real-world data observational |
| title | An observational study of haemophilia A patients without inhibitors using the French national claims (SNDS) database |
| title_full | An observational study of haemophilia A patients without inhibitors using the French national claims (SNDS) database |
| title_fullStr | An observational study of haemophilia A patients without inhibitors using the French national claims (SNDS) database |
| title_full_unstemmed | An observational study of haemophilia A patients without inhibitors using the French national claims (SNDS) database |
| title_short | An observational study of haemophilia A patients without inhibitors using the French national claims (SNDS) database |
| title_sort | observational study of haemophilia a patients without inhibitors using the french national claims snds database |
| topic | Haemophilia factor replacement therapy real-world data observational |
| url | https://www.tandfonline.com/doi/10.1080/16078454.2024.2320610 |
| work_keys_str_mv | AT marctrossaert anobservationalstudyofhaemophiliaapatientswithoutinhibitorsusingthefrenchnationalclaimssndsdatabase AT alettafalk anobservationalstudyofhaemophiliaapatientswithoutinhibitorsusingthefrenchnationalclaimssndsdatabase AT laurenegautier anobservationalstudyofhaemophiliaapatientswithoutinhibitorsusingthefrenchnationalclaimssndsdatabase AT nanakragh anobservationalstudyofhaemophiliaapatientswithoutinhibitorsusingthefrenchnationalclaimssndsdatabase AT oliviavanhinloopen anobservationalstudyofhaemophiliaapatientswithoutinhibitorsusingthefrenchnationalclaimssndsdatabase AT remivarin anobservationalstudyofhaemophiliaapatientswithoutinhibitorsusingthefrenchnationalclaimssndsdatabase AT marctrossaert observationalstudyofhaemophiliaapatientswithoutinhibitorsusingthefrenchnationalclaimssndsdatabase AT alettafalk observationalstudyofhaemophiliaapatientswithoutinhibitorsusingthefrenchnationalclaimssndsdatabase AT laurenegautier observationalstudyofhaemophiliaapatientswithoutinhibitorsusingthefrenchnationalclaimssndsdatabase AT nanakragh observationalstudyofhaemophiliaapatientswithoutinhibitorsusingthefrenchnationalclaimssndsdatabase AT oliviavanhinloopen observationalstudyofhaemophiliaapatientswithoutinhibitorsusingthefrenchnationalclaimssndsdatabase AT remivarin observationalstudyofhaemophiliaapatientswithoutinhibitorsusingthefrenchnationalclaimssndsdatabase |